home / stock / fulc / fulc articles
?Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod toward...
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. United Natural F...
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. Shares of Box, Inc. (NYSE: BOX) rose sharply during W...
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. AAR reported ...
CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company f...
CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company ...
CAMBRIDGE, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company ...
NEW YORK, Sept. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Lifshitz Law PLLC announces investigation into possible s...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
2024-03-27 20:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
?Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod toward...
―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will cont...